

Eur J Clin Chem Clin Biochem
1995; 33:271–274

© 1995 Walter de Gruyter & Co.
Berlin · New York

Serum Phospholipases A₂ after Aortobifemoral Reconstruction

By Juha M. Grönroos¹, Kari Kuttila¹, Juha Perttilä² and Timo J. Nevalainen³

¹ Department of Surgery

² Department of Anaesthesiology

³ Department of Pathology

University of Turku, Finland

(Received November 25, 1994/February 27, 1995)

Summary: Phospholipase A₂ has been implicated in the pathogenesis of local and distant tissue injury after ischaemia and reperfusion. A common operation inducing ischaemia and reperfusion is aortobifemoral reconstruction, during which the aorta is clamped and the blood supply via the inferior mesenteric artery and iliac arteries is interrupted. The purpose of the present work was to study the catalytic activity concentration of phospholipase A₂ and the mass concentrations of group I and group II phospholipases A₂ in the sera of patients undergoing aortobifemoral reconstruction. Both the catalytic activity concentration of phospholipase A₂ and the mass concentrations of group I and group II phospholipases A₂ increased in serum samples after the operation. The catalytic activity concentration of phospholipase A₂ correlated well with group II phospholipase A₂ mass values ($r = 0.81$, $p < 0.001$), whereas no correlation was found between the catalytic activity concentration of phospholipase A₂ and group I phospholipase A₂ mass values ($r = 0.12$, $p = 0.54$). The results emphasize the role of group II phospholipase A₂ in tissue injury after ischaemia and reperfusion.

Introduction

Phospholipases are hydrolytic enzymes widespread in nature. Phospholipids are the main lipid constituents of all cell membranes and phospholipases control a number of vital cell functions including membrane and cell integrity, signal transduction, secretion, prostaglandin synthesis and cell proliferation (1–5). Phospholipase A₂ is an enzyme of considerable interest with regard to the pathogenesis of various diseases, since its reaction products, lysophospholipids and non-esterified fatty acids, are highly cytotoxic substances (6).

Phospholipase A₂ has been postulated to be involved in the development of tissue injury after ischaemia and reperfusion (7–11). Phospholipase A₂ inhibitors effectively decrease local (7, 12) and distant (10) tissue damage after ischaemia and reperfusion.

Secretory, small molecular mass (M_r 14 000) phospholipases A₂ can be divided into group I phospholipases A₂

and group II phospholipases A₂ based on their amino acid sequences (13). The recent development of specific immunoassays of group I and group II phospholipases A₂ significantly contributed to studies on the role(s) of these enzymes in various diseases. The best characterized function of group I phospholipase A₂ is digestion of the phospholipid component of dietary fat (14), but the enzyme also functions as a growth factor (1) and vasoactive substance (15), and stimulates prostaglandin synthesis (16). Group II phospholipase A₂ is involved in the inflammatory reaction (17), but the details of the role of group II phospholipase A₂ are unknown. The amount of group II phospholipase A₂ is markedly increased in serum during infection and inflammation (17, 18), and the enzyme may function in defence against bacteria (19). Very high levels of circulating group II phospholipase A₂ are associated with sepsis, and a pivotal role was recently postulated for group II phospholipase A₂ in the pathogenesis of circulatory collapse in septic shock (20). The source of group I phos-

pholipase A₂ found in serum is the pancreas, whereas the source of group II phospholipase A₂ is unknown. Further, it is not known which of these secretory phospholipases A₂ is responsible for the increased catalytic activity concentration of phospholipase A₂ in serum after ischaemia and reperfusion. It has been hypothesized that activated pancreatic digestive enzymes such as group I phospholipase A₂ may play an important role in ischaemic intestinal injury by digesting various structures of mucosal cells (21).

A common operation inducing ischaemia and reperfusion in the descending colon and lower extremities is aortobifemoral reconstruction, during which the blood supply via the inferior mesenteric artery and iliac arteries is interrupted. The purpose of the present work was to study the catalytic activity concentration of phospholipase A₂ and the mass concentrations of group I and group II phospholipases A₂ in sera of patients undergoing aortobifemoral reconstruction. Specifically, the questions to be answered were: Does the catalytic activity concentration of phospholipase A₂ change in sera of patients undergoing aortobifemoral reconstruction? Which one of the secretory phospholipases A₂ (group I or II) is involved?

Patients and Methods

Ten consecutive patients undergoing aortobifemoral reconstruction with Y-prosthesis for aortoiliac occlusive disease (n = 8) or aortic aneurysm (n = 2) in the University Central Hospital of Turku were enrolled in the present study. The mean age of the patients was 55 (range 45–69) years and there were six females and four males. The study was approved by the local Ethical Committee and an informed consent was obtained from each patient.

The Y-prosthesis was anastomosed end-to-end to the aorta below the origins of renal arteries and the distal anastomoses were reconstructed during the same aortic cross-clamp. The inferior mesenteric artery was ligated at its origin from the aorta in patients with aortic aneurysm, whereas the blood flow to the inferior mesenteric artery was established at reperfusion via the stenotic iliac arteries in patients operated for arteriosclerotic disease.

The operations were performed under general anaesthesia with thiopentone, pancuronium, fentanyl, dehydrobenzperidol, enflurane (volume fraction 0.005–0.01) and nitrous oxide (volume fraction 0.70) plus oxygen (volume fraction 0.30). The patients had a catheter inserted into a radial artery for haemodynamic monitoring. End-tidal CO₂ was monitored and kept at a level of normoventilation (4.5–5.5 kPa). Blood loss was replaced with Ringer's acetate solution and with packed red blood cells, when necessary, to maintain the blood haemoglobin concentration above 100 g/l. After the operation, atropine and neostigmine were used to reverse the neuromuscular blockade and the patients were extubated in the operating room. The mean blood loss was 1400 (range 100–5800) ml, operation time 161 (125–185) min, aortic clamping time 61 (39–106) min and the deepest fall in blood pressure after aortic declamping 37 (10–75) mmHg. All the patients recovered uneventfully.

Blood samples were withdrawn before the operation, before aortic clamping, after declamping, three and six hours after declamping, and thereafter daily until the eighth postoperative day to determine the catalytic activity concentration of phospholipase A₂ and the

mass concentrations of group I and group II phospholipases A₂ in serum. The catalytic activity concentration of phospholipase A₂ was assayed by using micellar radioactive phosphatidylcholine as a substrate (22). The mass concentrations of group I and group II phospholipases A₂ were measured by time-resolved fluoroimmunoassays as described earlier (23, 24). The serum samples were stored at –20 °C until assayed.

The results are expressed as mean ± SEM. The significance of the time-related changes was tested by the analysis of variance (ANOVA) with repeated measurements. *Newman-Keuls'* multiple range test was used to test differences between the preoperative and other values. *Pearson's* linear correlation was used to study the correlations between the catalytic activity concentration of




Fig. 1 Group I phospholipase A₂, group II phospholipase A₂ mass concentration and the catalytic activity concentration of phospholipase A₂ in sera of ten consecutive patients undergoing aortobifemoral reconstruction (mean ± SEM). * p < 0.05 and ** p < 0.01 compared with the preoperative values (*Newman-Keuls'* multiple range test).

phospholipase A₂ and the mass concentrations of group I and group II phospholipase A₂.

Results

Figure 1 shows the mass concentrations of group I and group II phospholipases A₂ and the catalytic activity concentration of phospholipase A₂ in sera of the operated patients. The mass concentrations of group I and group II phospholipases A₂ and the catalytic activity concentration of phospholipase A₂ increased steadily during days 1–4 after the operation and decreased thereafter ($p < 0.001$). The mass concentration of group II phospholipase A₂ and the catalytic activity concentration of phospholipase A₂ changed in concert and reached in their peak values on the fourth postoperative day, while the mass concentration of group I phospholipase A₂ reached its maximum at the second postoperative day. The patients did not show any clinical signs of postoperative pancreatitis.

The catalytic activity concentration of phospholipase A₂ correlated well with the mass concentration of group II phospholipase A₂ in the regression analysis (fig. 2; $r = 0.81$, $p < 0.001$), whereas there was no correlation between the catalytic activity concentration of phospholipase A₂ and the mass concentration of group I phospholipase A₂ (fig. 3; $r = 0.12$, $p = 0.54$).

Discussion

Increased phospholipase A₂ activity seems to be instrumental for the development of ischaemic intestinal injury (11). Phospholipase A₂ inhibitors effectively decrease tissue damage and the increase in mucosal permeability in experimental intestinal ischaemia (7, 12). Moreover, increase of phospholipase A₂ activity is re-

garded a crucial step in the pathogenesis of distant organ injury after ischaemia and reperfusion, since phospholipase A₂ inhibition prevented lung injury after ischaemia and reperfusion of the gut (10). Phospholipase A₂ is involved in the generation of a variety of bioactive and potentially toxic lipid metabolites, such as arachidonic acid metabolites, lysophospholipids, and platelet-activating factor (6), which may play a role in local and distant tissue injury after ischaemia and reperfusion. In addition, damage at the mucosal layer of the intestine allows enhanced uptake of bacteria and endotoxins from the intestinal lumen into circulation (25), which, in turn, increases the formation of inflammatory mediators such as phospholipase A₂ leading to a decrease in blood pressure and circulation (20). These changes may create a vicious circle in which impaired intestinal perfusion leads to a progressive damage of intestinal mucosal cells resulting ultimately in bowel infarction. In aortobifemoral reconstruction, the blood supply from the inferior mesenteric artery is interrupted, and, thus, this operation always induces left colonic ischaemia to some extent. Although the resulting ischaemic colonic injury usually runs a benign course, a fulminant disease develops in a minority of patients. This may prove fatal in spite of prompt surgical intervention. The results of the current study emphasize the role of group II phospholipase A₂ in tissue injury after ischaemia and reperfusion.

The mass concentration of group I phospholipase A₂ increased in sera of patients after aortobifemoral reconstruction in the current study, but no clinical signs of postoperative pancreatitis were noticed. The slight increase in serum group I phospholipase A₂ mass concentration may be due to pancreatic irritation during the operation. Group I phospholipase A₂ mass concentration values did not correlate with the catalytic activity con-




Fig. 2 Linear regression between the catalytic activity concentration of phospholipase A₂ and the mass concentration of group II phospholipase A₂ in sera of patients undergoing aortobifemoral reconstruction ($r = 0.81$, $p < 0.001$).




Fig. 3 Linear regression between the catalytic activity concentration of phospholipase A₂ and the mass concentration of group I phospholipase A₂ in sera of patients undergoing aortobifemoral reconstruction ($r = 0.12$, $p = 0.54$).

centration of phospholipase A₂. The results of the current study do not support the formerly presented idea (21) that activated/increased pancreatic digestive enzymes such as group I phospholipase A₂ may play an important role in ischaemic intestinal injury.

The current results show that the catalytic activity concentration of phospholipase A₂ and the mass concentrations of group I and group II phospholipases A₂ increase in sera of patients after aortobifemoral reconstruction. The catalytic activity concentration of phospholipase A₂ correlates well with the mass concentration of group II phospholipase A₂ but not with the mass concentration

of group I phospholipase A₂ in sera of these patients. These results indicate that the increase in the catalytic activity concentration of phospholipase A₂ is due to group II phospholipase A₂. We conclude that group II phospholipase A₂ may be involved in the development of local and distant tissue injury after ischaemia and reperfusion.

Acknowledgements

This study was supported by The Finnish Foundation for Alcohol Studies.

References

1. Arita H, Hanasaki K, Nakano T, Oka S, Teraoka H, Matsumoto K. Novel proliferative effect of phospholipase A₂ in Swiss 3T3 cells via specific binding site. *J Biol Chem* 1991; 266:19239–41.
2. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature* 1984; 312:315–21.
3. Dennis EA. Regulation of eicosanoid production: role of phospholipases and inhibitors. *Biotechnology* 1987; 5:1294–300.
4. Liscovitch M. Crosstalk among multiple signal-activated phospholipases. *Trends Biochem Sci* 1992; 17:393–9.
5. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science* 1992; 258:607–14.
6. Benveniste J, Chignard M, Le Couedic J, Vargaftig B. Biosynthesis of platelet-activating factor (PAF-acether). II. Involvement of phospholipase A₂ in the formation of PAF-acether and lyso-PAF-acether from rabbit platelets. *Thromb Res* 1982; 25:375–85.
7. Otamiri T, Tagesson C. Role of phospholipase A₂ and oxygenated free radicals in mucosal damage after small intestinal ischemia and reperfusion. *Am J Surg* 1989; 157:562–6.
8. Hotter G, Leon OS, Rosello-Catafau J, Lopez-Boado MA, Parrellada PP, Henriques RD, et al. Tissue prostanoic release, phospholipase A₂ activity and lipid peroxidation in pancreas transplantation. *Transplantation* 1991; 51:987–90.
9. Taoka H. Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A₂. *Gastroenterol Jpn* 1991; 26:633–44.
10. Koike K, Moore EE, Moore FA, Carl VS, Pitman JM, Banerjee A. Phospholipase A₂ inhibition decouples lung injury from gut ischemia-reperfusion. *Surgery* 1992; 112:173–80.
11. Schoenberg MH, Berger HG. Reperfusion injury after intestinal ischemia. *Crit Care Med* 1993; 21:1376–86.
12. Otamiri T, Franzén L, Lindmark D, Tagesson C. Increased phospholipase A₂ and decreased lysophospholipase activity in the small intestinal mucosa after ischemia and revascularization. *Gut* 1987; 28:1445–53.
13. Heinrikson RL, Krueger ET, Keim PS. Amino acid sequence of phospholipase A₂-α from the venom of *Crotalus adamanteus*: a new classification of phospholipases A₂ based upon structural determinants. *J Biol Chem* 1977; 252:4913–21.
14. van den Bosch H. Intracellular phospholipases A. *Biochim Biophys Acta* 1980; 604:191–246.
15. Nakajima M, Hanasaki K, Ueda M, Arita H. Effect of pancreatic type phospholipase A₂ on isolated porcine cerebral arteries via its specific binding sites. *FEBS Lett* 1992; 309:261–4.
16. Sommers CD, Bobbitt JL, Bemis KG, Synder DW. Porcine pancreatic phospholipase A₂-induced contractions of guinea pig lung pleural strips. *Eur J Pharmacol* 1992; 216:87–96.
17. Nevalainen TJ. Serum phospholipases A₂ in inflammatory diseases. *Clin Chem* 1993; 39:2453–9.
18. Grönroos JM, Kuttala K, Nevalainen TJ. Group II phospholipase A₂ in serum in critically ill surgical patients. *Crit Care Med* 1994; 22:956–9.
19. Wright GW, Ooi CE, Weiss J, Elsbach P. Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A₂ that participate in the destruction of *Escherichia coli* in a rabbit inflammatory exudate. *J Biol Chem* 1990; 265:6675–81.
20. Vadas P, Pruzanski W. Induction of group II phospholipase A₂ expression and pathogenesis of the sepsis syndrome. *Circ Shock* 1993; 39:160–7.
21. Bounous G. Pancreatic proteases and oxygen derived free radicals in acute ischemic enteropathy. *Surgery* 1986; 90:92–4.
22. Schädlich HR, Büchler M, Beger HG. Improved method for the determination of phospholipase A₂ catalytic activity concentration in human serum and ascites. *J Clin Chem Clin Biochem* 1987; 25:505–9.
23. Santavuori AS, Kortesoja PT, Eskola JU, Nevalainen TJ. Application of a new monoclonal antibody for time-resolved fluoroimmunoassay of human pancreatic phospholipase A₂. *Eur J Clin Chem Clin Biochem* 1991; 29:819–26.
24. Nevalainen TJ, Kortesoja PT, Rintala E, Mäki F. Immunochemical detection of group I and group II phospholipases A₂ in human serum. *Clin Chem* 1992; 38:1824–9.
25. Bounous G. Role of intestinal contents in the pathophysiology of acute intestinal ischemia. *Am J Surg* 1967; 114:368–75.

Dr. Juha M. Grönroos
Department of Surgery
University of Turku
Kiinamyllynkatu 4–8
FIN-20520 Turku
Finland